Advertisements



Why Celldex Therapeutics Is Getting Crushed

Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study......»»

Category: blogSource: 247wallstApr 16th, 2018

Why Ovid Therapeutics Is Monday’s Big Biotech Loser

Ovid Therapeutics shares were crushed to start the week even though the company announced positive midstage results for its Angelman syndrome study......»»

Category: blogSource: 247wallstAug 6th, 2018

Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics

Which beaten-down biotech stock wins in a head-to-head match-up?.....»»

Category: topSource: foxnewsJun 29th, 2018

Why Summit Therapeutics Was Crushed

Summit Therapeutics is another biopharma company that is paying the price on Wednesday......»»

Category: blogSource: 247wallstJun 27th, 2018

Celldex Therapeutics Salvage Value

Celldex Therapeutics Salvage Value.....»»

Category: topSource: seekingalphaJun 15th, 2018

Celldex Therapeutics (CLDX) Down 9.2% Since Earnings Report: Can It Rebound?

Zacks.....»»

Category: topSource: redinewsJun 11th, 2018

Why Melinta Therapeutics Shares Are Getting Crushed

Melinta Therapeutics saw its shares plunge on Thursday after the firm announced that it had priced a secondary offering......»»

Category: blogSource: 247wallstMay 24th, 2018

What"s in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on i.....»»

Category: personnelSource: nytMay 3rd, 2018

MGIC, Juniper Networks Slide into Wednesday’s 52-Week Low Club

MGIC Investment Group, Celldex Therapeutics, Juniper Networks, and Healthcare Services Group all posted new 52-week lows on Wednesday......»»

Category: blogSource: 247wallstApr 18th, 2018

Celldex"s Phase II Breast Cancer Study Fails, Shares Plunge

Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastat.....»»

Category: smallbizSource: nytApr 17th, 2018

Celldex, Acacia Plummet into Monday’s 52-Week Low Club

Celldex Therapeutics, Acacia Communications, Apricus Biosciences, and Ctrp.com all posted new 52-week lows Monday......»»

Category: blogSource: 247wallstApr 16th, 2018

Celldex"s stock plummets toward record low after failed drug study

Shares of Celldex Therapeutics Inc. plummeted 40% in premarket trade Monday toward a record low, after the drug.....»»

Category: topSource: marketwatchApr 16th, 2018

Commit To Purchase Spark Therapeutics At $45, Earn 12.8% Annualized Using Options

Stock Options Channel.....»»

Category: topSource: redinewsSep 22nd, 2018

Commit To Buy Melinta Therapeutics At $2.50, Earn 17.5% Annualized Using Options

Stock Options Channel.....»»

Category: topSource: redinewsSep 22nd, 2018

Commit To Buy Seres Therapeutics At $5, Earn 14% Annualized Using Options

Stock Options Channel.....»»

Category: topSource: redinewsSep 22nd, 2018

Oversold Conditions For Global Blood Therapeutics (GBT)

Dividend Channel.....»»

Category: topSource: redinewsSep 22nd, 2018

Cytori Therapeutics files to sell 3.73M shares of common stock for holders

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 21st, 2018

Armistice Capital reports 5.3% passive stake in Voyager Therapeutics

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 21st, 2018

Biotech developing cancer drugs kicks off $13M round with $5K pitch contest win

Rockville-based biotechnology company Remedy Plan Therapeutics took home $5,000 Thursday as the winner of the Maryland Tech Council's inaugural Bio+Tech18 pitch competition. That money will go toward a larger, $13 million round the company is looking .....»»

Category: topSource: bizjournalsSep 21st, 2018

Nightstar Therapeutics to host research and development day

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 21st, 2018

Y-mAbs Therapeutics opens at $26.50, IPO priced at $16.00 per share

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 21st, 2018